AbbVie Expects $291 Million Impact on Q2 2026 EPS
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
In a regulatory filing, AbbVie said that reported GAAP earnings and adjusted non-GAAP earnings for the second quarter of 2026 are expected to include acquired IPR&D and milestones expense of $291 million on a pre-tax basis, representing an unfavorable impact of $0.17 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended June 30, 2026 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates. While acquired IPR&D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR&D and milestones expense due to uncertainty of the future occurrence and timing of these transactions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to fall
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 261.070
Low
223.00
Averages
252.00
High
289.00
Current: 261.070
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TEPKINLY Receives EU Approval for Relapsed Lymphoma Treatment
- Clinical Trial Results: The EPCORE FL-1 trial demonstrated that TEPKINLY in combination with lenalidomide and rituximab reduced the risk of disease progression or death by 79% (HR 0.21), indicating a significant improvement in treatment outcomes for patients with relapsed lymphoma and suggesting a paradigm shift in therapy.
- Impressive Efficacy Data: The overall response rate (ORR) for patients treated with TEPKINLY + R2 was 96%, significantly higher than the 81% observed with R2 alone, indicating that TEPKINLY offers a more effective treatment option that could enhance patient survival.
- Safety Profile Analysis: While 44% of patients experienced serious adverse reactions, the safety profile of TEPKINLY was consistent with known profiles of the individual agents, establishing its acceptability for clinical use and paving the way for broader application.
- Broad Market Potential: The approval of TEPKINLY not only provides a new treatment option for patients across Europe but also reflects AbbVie's ongoing innovation in oncology, which is expected to drive further expansion in the global market.
See More
AbbVie Receives EU Approval for TEPKINLY in Follicular Lymphoma Treatment
- New Drug Approval: AbbVie announced that TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab has received marketing authorization in the EU for treating relapsed or refractory follicular lymphoma, marking a significant advancement in treatment options.
- Clinical Trial Results: The EPCORE FL-1 trial demonstrated that TEPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, p<0.0001), highlighting its substantial potential in improving patient outcomes.
- Efficacy Highlights: The overall response rate for TEPKINLY + R2 was 96%, compared to 81% for R2 alone, indicating that the combination therapy may offer patients a higher chance of achieving remission.
- Safety Profile: While the safety of TEPKINLY + R2 aligns with known profiles of the individual agents, 44% of patients experienced serious adverse reactions, underscoring the need for careful monitoring of patient health during clinical use.
See More
iShares Core High Dividend ETF Outperforms S&P 500
- Market Outperformance: The iShares Core High Dividend ETF has risen over 15% this year, significantly outperforming the S&P 500's 9% increase, highlighting its investment advantage in high-yield stocks and attracting more income-seeking investors.
- Quality Stock Selection: This ETF tracks an index of high-yield U.S. dividend stocks, currently holding 75 stocks with an annual dividend yield of 2.9%, nearly three times that of the S&P 500, indicating its strong competitive edge in dividend investing.
- Sector Drivers: The fund's high exposure to energy stocks, particularly ExxonMobil and Chevron, which are up 14% and 11% respectively, has significantly boosted its performance, while strong gains from healthcare stocks like AbbVie and Merck have also contributed to its growth.
- Growth Potential: Since its inception in 2011, the iShares Core High Dividend ETF has delivered over 10% annualized returns, and with its focus on high-quality dividend stocks, it is expected to continue providing stable income and growth opportunities for investors.
See More
iShares Core High Dividend ETF Surges Over 15% Year-to-Date
- High-Yield Stock Advantage: The iShares Core High Dividend ETF has surged over 15% this year, primarily benefiting from its higher exposure to high-yield energy stocks, particularly ExxonMobil and Chevron, which have risen 14% and 11% respectively, thus driving the fund's overall performance.
- Healthcare Stock Contribution: The ETF has also gained from its significant allocation to healthcare stocks, notably AbbVie and Merck, with AbbVie shares up over 14% and Merck up over 23%, indicating that high-quality dividend stocks can deliver substantial total returns.
- Dividend Yield Comparison: The iShares Core High Dividend ETF currently boasts a dividend yield of 2.9%, nearly three times the S&P 500's yield of 1.1%, highlighting its advantage in providing stable cash flow, which attracts income-seeking investors.
- Strong Long-Term Performance: Since its inception in 2011, the ETF has delivered over 10% annualized returns over the past one, three, and five years, indicating success in its investment strategy focused on high-quality dividend stocks, and it is expected to continue providing strong returns in the future.
See More
Apple's Stock Decline Raises Investor Concerns
- Market Capital Loss: Apple lost approximately $500 billion in market cap over 25 days in June, equivalent to the total market value of AbbVie, Caterpillar, or Mastercard, indicating heightened investor concerns about its future performance.
- Price Increase Impact: The company announced price hikes for its Mac and iPad products, with CEO Tim Cook describing the memory and storage shortage as a 'hundred-year flood,' which could significantly impact iPhone pricing and increase consumer purchasing pressure.
- Investor Confidence Shaken: Although historically, pullbacks in Apple stock have presented buying opportunities, current market conditions and competitive pressures have led to investor doubts about the new Siri's launch and product appeal, resulting in a 2.6% decline in stock price.
- Analyst Outlook: Despite the challenges, 62% of analysts still rate Apple as a 'buy' or 'strong buy,' reflecting confidence in its long-term prospects, with a consensus 12-month price target suggesting over 10% upside potential.
See More
Apple Loses $500 Billion Market Cap Amid AI Concerns
- Significant Market Cap Loss: Apple lost approximately $500 billion in market cap over 25 days in June, equivalent to the total market cap of AbbVie, Caterpillar, or Mastercard, indicating substantial market concerns regarding its future performance.
- Uncertainty Over Siri Update: The lack of a clear timeline for the new Siri version discussed at the 2026 Worldwide Developers Conference led to a 2.6% drop in stock price, reflecting investor skepticism about Apple's AI capabilities and potential customer excitement.
- Price Increases Announced: Apple announced price hikes for its Mac and iPad products due to a surge in memory and storage demand, with CEO Tim Cook describing the shortage as a
See More
TEPKINLY Receives EU Approval for Relapsed Lymphoma Treatment
- Clinical Trial Results: The EPCORE FL-1 trial demonstrated that TEPKINLY in combination with lenalidomide and rituximab reduced the risk of disease progression or death by 79% (HR 0.21), indicating a significant improvement in treatment outcomes for patients with relapsed lymphoma and suggesting a paradigm shift in therapy.
- Impressive Efficacy Data: The overall response rate (ORR) for patients treated with TEPKINLY + R2 was 96%, significantly higher than the 81% observed with R2 alone, indicating that TEPKINLY offers a more effective treatment option that could enhance patient survival.
- Safety Profile Analysis: While 44% of patients experienced serious adverse reactions, the safety profile of TEPKINLY was consistent with known profiles of the individual agents, establishing its acceptability for clinical use and paving the way for broader application.
- Broad Market Potential: The approval of TEPKINLY not only provides a new treatment option for patients across Europe but also reflects AbbVie's ongoing innovation in oncology, which is expected to drive further expansion in the global market.
See More
AbbVie Receives EU Approval for TEPKINLY in Follicular Lymphoma Treatment
- New Drug Approval: AbbVie announced that TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab has received marketing authorization in the EU for treating relapsed or refractory follicular lymphoma, marking a significant advancement in treatment options.
- Clinical Trial Results: The EPCORE FL-1 trial demonstrated that TEPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21, p<0.0001), highlighting its substantial potential in improving patient outcomes.
- Efficacy Highlights: The overall response rate for TEPKINLY + R2 was 96%, compared to 81% for R2 alone, indicating that the combination therapy may offer patients a higher chance of achieving remission.
- Safety Profile: While the safety of TEPKINLY + R2 aligns with known profiles of the individual agents, 44% of patients experienced serious adverse reactions, underscoring the need for careful monitoring of patient health during clinical use.
See More
iShares Core High Dividend ETF Outperforms S&P 500
- Market Outperformance: The iShares Core High Dividend ETF has risen over 15% this year, significantly outperforming the S&P 500's 9% increase, highlighting its investment advantage in high-yield stocks and attracting more income-seeking investors.
- Quality Stock Selection: This ETF tracks an index of high-yield U.S. dividend stocks, currently holding 75 stocks with an annual dividend yield of 2.9%, nearly three times that of the S&P 500, indicating its strong competitive edge in dividend investing.
- Sector Drivers: The fund's high exposure to energy stocks, particularly ExxonMobil and Chevron, which are up 14% and 11% respectively, has significantly boosted its performance, while strong gains from healthcare stocks like AbbVie and Merck have also contributed to its growth.
- Growth Potential: Since its inception in 2011, the iShares Core High Dividend ETF has delivered over 10% annualized returns, and with its focus on high-quality dividend stocks, it is expected to continue providing stable income and growth opportunities for investors.
See More
iShares Core High Dividend ETF Surges Over 15% Year-to-Date
- High-Yield Stock Advantage: The iShares Core High Dividend ETF has surged over 15% this year, primarily benefiting from its higher exposure to high-yield energy stocks, particularly ExxonMobil and Chevron, which have risen 14% and 11% respectively, thus driving the fund's overall performance.
- Healthcare Stock Contribution: The ETF has also gained from its significant allocation to healthcare stocks, notably AbbVie and Merck, with AbbVie shares up over 14% and Merck up over 23%, indicating that high-quality dividend stocks can deliver substantial total returns.
- Dividend Yield Comparison: The iShares Core High Dividend ETF currently boasts a dividend yield of 2.9%, nearly three times the S&P 500's yield of 1.1%, highlighting its advantage in providing stable cash flow, which attracts income-seeking investors.
- Strong Long-Term Performance: Since its inception in 2011, the ETF has delivered over 10% annualized returns over the past one, three, and five years, indicating success in its investment strategy focused on high-quality dividend stocks, and it is expected to continue providing strong returns in the future.
See More
Apple's Stock Decline Raises Investor Concerns
- Market Capital Loss: Apple lost approximately $500 billion in market cap over 25 days in June, equivalent to the total market value of AbbVie, Caterpillar, or Mastercard, indicating heightened investor concerns about its future performance.
- Price Increase Impact: The company announced price hikes for its Mac and iPad products, with CEO Tim Cook describing the memory and storage shortage as a 'hundred-year flood,' which could significantly impact iPhone pricing and increase consumer purchasing pressure.
- Investor Confidence Shaken: Although historically, pullbacks in Apple stock have presented buying opportunities, current market conditions and competitive pressures have led to investor doubts about the new Siri's launch and product appeal, resulting in a 2.6% decline in stock price.
- Analyst Outlook: Despite the challenges, 62% of analysts still rate Apple as a 'buy' or 'strong buy,' reflecting confidence in its long-term prospects, with a consensus 12-month price target suggesting over 10% upside potential.
See More
Apple Loses $500 Billion Market Cap Amid AI Concerns
- Significant Market Cap Loss: Apple lost approximately $500 billion in market cap over 25 days in June, equivalent to the total market cap of AbbVie, Caterpillar, or Mastercard, indicating substantial market concerns regarding its future performance.
- Uncertainty Over Siri Update: The lack of a clear timeline for the new Siri version discussed at the 2026 Worldwide Developers Conference led to a 2.6% drop in stock price, reflecting investor skepticism about Apple's AI capabilities and potential customer excitement.
- Price Increases Announced: Apple announced price hikes for its Mac and iPad products due to a surge in memory and storage demand, with CEO Tim Cook describing the shortage as a
See More
